Dinakara Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 8.05 Cr
as on 23-06-2024
- Paid Up Capital ₹ 6.00 Cr
as on 23-06-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 7.65 Cr
as on 23-06-2024
- Revenue 19.53%
(FY 2023)
- Profit -359.75%
(FY 2023)
- Ebitda -11.66%
(FY 2023)
- Net Worth -5.99%
(FY 2023)
- Total Assets 53.08%
(FY 2023)
About Dinakara Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.05 Cr and a paid-up capital of Rs 6.00 Cr.
The company has closed loans amounting to ₹7.65 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Kavita Pidimarri and Mahesh Pidimarri serve as directors at the Company.
- CIN/LLPIN
U24100TG2017PTC115562
- Company No.
115562
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Mar 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dinakara Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kavita Pidimarri  | Director | 17-Jan-2024 | Current |
| Mahesh Pidimarri | Director | 17-Jan-2024 | Current |
Financial Performance and Corporate Structure Insights of Dinakara Life Sciences.
Dinakara Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.53% increase. The company also saw a substantial fall in profitability, with a 359.75% decrease in profit. The company's net worth dipped by a decrease of 5.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dinakara Life Sciences?
In 2023, Dinakara Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Viruj Chematrix Private LimitedActive 3 years 2 monthsKavita Pidimarri and Mahesh Pidimarri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Mar 2018 | ₹7.65 Cr | Satisfied |
How Many Employees Work at Dinakara Life Sciences?
Dinakara Life Sciences has a workforce of 22 employees as of Apr 26, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dinakara Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dinakara Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
